Previous 10 | Next 10 |
BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies BeiGene Ltd. ( BGNE ) announced that it has inked a new deal with Singlomics Biopharmaceuticals Co. for developing, manufacturing and commercializing various anti-COVID-19 antibodies, including DXP-593 and DXP-604. U...
Matinas BioPharma (NYSEMKT: MTNB ) has completed enrollment in an open-label 100-subject Phase 2 clinical trial, ENHANCE-IT , comparing the effectiveness of lead candidate MAT9001 to Amarin's (NASDAQ: AMRN ) Vascepa (icosapent ethyl) in reducing triglyceride levels and other lipid m...
BEDMINSTER, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has completed enrollment in the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in A...
BEDMINSTER, N.J., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview and host one-on-one meetings during two upcoming virtual investor confe...
Matinas BioPharma ( MTNB +1.0% ) has announced online publication of data from Phase 1 portion of the EnACT study for MAT2203, in Antimicrobial Agents and Chemotherapy , a journal of the American Society of Microbiology . More news on: Matinas BioPharma Holdings, Inc., Healthcare s...
BEDMINSTER, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the publication of data from the Phase 1 portion of the EnACT (Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial) study for MAT2203, a novel oral formul...
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2020 Earnings Conference Call August 10, 2020, 04:30 PM ET Company Participants Peter Vozzo - IR Jerry Jabbour - CEO Terri Matkovits - Chief Development Officer Conference Call Participants Michael Okunewitch - Maxim Group Gregg ...
Matinas Biopharma (NYSEMKT: MTNB ) : Q2 GAAP EPS of -$0.03 in-line. More news on: Matinas BioPharma Holdings, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– ENHANCE-IT study of MAT9001 against Vascepa ® expected to be fully enrolled in August 2020; topline data anticipated Q1 2021 – – EnACT study of MAT2203 in cryptococcal meningitis resumed enrollment; on track for potential cohort progression Q4 2020 –...
4 Cheap Stocks To Watch This Week Penny stocks are definitely considered “affordable” but let’s not get than confused with “cheap”. When it comes to these small- and micro-cap companies, the price tag of the stock itself shouldn’t be the only thing y...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...